Back to search

Netherlands· NL-3972817d83ab

Moventig 12,5 mg filmomhulde tabletten

A naloxegol product containing naloxegoloxalaat, registered in Netherlands by Grunenthal GmbH. The same ATC class is registered in 15 of our 19 countries.

ATC A06AH03

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedMoventig 12,5 mg filmomhulde tablettenATCA06AH03REGISTER NO.NL-3972817d83abPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Naloxegol is registered in 15 of 19 countries.

Countries holding a registration under ATC A06AH03 (naloxegol), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose

Naloxegol · ATC A06AH03

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of naloxegol costs, country by country.

Normalised to the WHO defined daily dose (25 mg), the median price runs from $3.62 in Italy to $5.84 in Spain — a ×1.6 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Naloxegol · price per daily dose (25 mg)

USD · FX 28 Sept 2026

  • ES Spain$5.84
  • CH Switzerland$5.75
  • FR France$3.80
  • IT Italy$3.62
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
NALOXEGOLOXALAAT
Manufacturer
Grunenthal GmbH
Country
Netherlands (NL)
ATC code
A06AH03
ATC class
Naloxegol
Defined daily dose
25 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/14/962

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

204 interactions on record for naloxegol.

Graded by severity as the source publishes them — 66 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Naloxegol · interactions on record

204 records

  • 66 severe
  • 57 moderate
  • 81 minor

Most severe, free to view

  • AprepitantA04AD12severe
  • DanazolG03XA01severe
  • LonafarnibA16AX20severe
  • BerotralstatB06AC06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Naloxegol in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All naloxegol products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Moventig
  • Iceland · Moventig
  • Liechtenstein · Moventig
  • Norway · Moventig

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9292079b-9ff2-480d-b1d2-365d566eed33
GET /v1/drugs/9292079b-9ff2-480d-b1d2-365d566eed33?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/moventig-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Naloxegol",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp114332",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "HYPROMELLOSE (E 464)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "MACROGOL 400",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MANNITOL (D-) (E 421)",
    "PROPYLGALLAAT (E 310)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "NALOXEGOLOXALAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2014/12/08",
  "procedure_number": "EMEA/H/C/002810",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/14/962",
  "additional_monitoring": "N"
}

See everything about naloxegol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.